Category Archives: Stem Cell Research

BEVERLY, MA and TORONTO, ON--(Marketwired - Sep 30, 2013) - Hamilton Thorne Ltd. (TSX VENTURE: HTL), a leading provider of precision laser devices and advanced image analysis systems for the fertility, stem cell and developmental biology research markets announced today that is has reached an agreement to amend (the "Debenture Amendments") its $300,000 unsecured subordinated debentures (the "Debentures") dated August 29, 2012. The Debenture Amendment: (i) extends the maturity date of the Debentures from October 1, 2013 to October 1, 2016; (ii) reduces the interest rate payable under the Debentures to 10% per annum effective October 1, 2013 until the maturity date; and (iii) amends interest payment terms so that interest to September 30, 2013 shall be accrued and paid only upon maturity or earlier redemption of the Debentures, while interest earned from and after October 1, 2013 shall be payable in arrears on a quarterly basis.All other terms and conditions of the Debentures, as amended, were ratified and confirmed. "We are pleased with the confidence and support shown by two of our major investors in extending and amending the terms of these debentures," said Michael Bruns, Chief Financial Officer of Hamilton Thorne Ltd."These changes have improved our balance sheet … Continue reading →

government funding of stem cell research Federal Grants, State Grants, Foundation Grants More! http://urlbit.es/govgrants Did you know that.... -- 15, 000, 000 individuals acquire free of charge a... By: Amy knowing … Continue reading →

JUPITER, Fla.--(BUSINESS WIRE)-- BioRestorative Therapies, Inc. ("BRT" or the "Company") (BRTX), a life sciences company focused on developing stem cell-based therapies for personal medical applications, announced the engagement of the regulatory consultancy firm Phil Triolo and Associates, LC (PTA) to help advance the Companys brtxDISC therapeutic procedure through the U.S. Food and Drug Administration (FDA) regulatory process. The brtxDISC program is the Companys non-surgical investigative treatment for bulging and herniated lumbar discs. Under the engagement, PTA will assist the Company in its efforts to obtain U.S. regulatory approval and to satisfy FDA regulations applicable to the Companys medical device used in the brtxDISC procedure, including the implementation of quality systems procedures. In addition, PTA will assist BRT in its efforts to satisfy FDA regulations relevant to the combination products (biologic plus device) it ultimately plans to commercialize in the U.S. PTA is also available to assist in any international regulatory approval processes the Company may pursue. This is an important step in advancing the development of our brtxDISC procedure, said Mark Weinreb, chief executive officer of BioRestorative Therapies. We have developed a minimally invasive, technologically innovative medical device to precisely deliver a patients own stem cells directly into the damaged … Continue reading →

President Obama on Stem Cell Research President Obama signed an order reversing the Bush administration's strict limits on human embryonic stem cell research. By: Purtier Testimonials … Continue reading →

Busy, Smart and Strong: Stem Cell Research By: KTARNews923 … Continue reading →

CARLSBAD, CA--(Marketwired - Sep 25, 2013) - International Stem Cell Corporation (OTCQB: ISCO) (www.internationalstemcell.com), a California-based biotechnology company developing novel stem cell based therapies, announced today that its chief scientific officer, Dr. Ruslan Semechkin, will present the latest results from its Parkinson's disease program at the American Neurological Association's 2013 Annual Meeting October 13 - 15, 2013 in New Orleans, LA. Conducted in collaboration with the Sanford Burnham Medical Research Institute, the presentation will include new data and results from ISCO's first primate study, including an outline of neural stem cells' unique mechanism of action, data on the fate of the cells and a detailed analysis of the primate's immune response to the implantation.The presentation will be at the following session: Date: Monday, October 14, 2013 Time: 11:00 am - 7:00 pm Title: The Use of Neural Stem Cells for the Treatment of Parkinson's Disease in a Non-Human Primate Model ISCO's Parkinson's disease program uses human parthenogenetic neural stem cells (hPNSC), a novel therapeutic cellular product derived from the company's proprietary histocompatible human pluripotent stem cells. The hPNSC are self-renewing multipotent cells that are precursors for the major cells of the central nervous system. The ability of hPNSC to (1) … Continue reading →

MIAMI, (PRWEB) September 25, 2013 Stem Cell Training, Inc., a division of the Global Stem Cells Group, today announced a newly formed alliance with Far Eastern University in Manila, Philippines for the advancement of stem call procedures. The alliance was established to train physicians and mid-level providers in techniques for harvesting and reintegrating stem cells derived from adipose (fat) tissue, bone marrow and dental pulp. Through the alliance, the Miami-based biotechnology training company has established a two-day, hands-on intensive training course for physicians and high level practitioners titled Adipose Derived Harvesting, Isolation and Re-integration Training Course, taught at the Far Eastern University School of Medicine. Conducted by Joseph Purita, M.D., a pioneer in the use of stem cells in orthopedics and founder of the Institute of Regenerative and Molecular Orthopedics in Boca Raton, Florida, the program covers all of the essentials necessary to perform adipose-derived stem cell protocols and bone marrow-derived stem cell harvesting, processing and activation procedures in a clinical environment. New classes are scheduled for September 24-25 and November 18-19, 2013 at Far Eastern University. Stem Cell Training, Inc. is a multi-dimensional company offering coursework and training in 35 cities worldwide. Coursework offered focuses on minimally invasive techniques … Continue reading →

Peter Zandstra receives the 2013 Till & McCulloch Award OTTAWA, Sept. 25, 2013 /CNW/ - A Canadian technology that has the potential to boost the number of stem cells given to patients undergoing transplants of the blood-forming system has been recognized as the most impactful stem cell research paper authored by a Canadian in the past year. Dr. Peter Zandstra has been given the 2013 Till & McCulloch Award in recognition of this contribution to global stem cell research. Dr. Zandstra will accept the award and present a lecture entitled "Engineering pluripotent stem cell derived microtissues" as part of the Till & McCulloch Meetings, Canada's premier stem cell event. Dr. Michael Rudnicki, Scientific Director of the Stem Cell Network, who launched the Till & McCulloch Award in 2005 and will make the award presentation, says the Zandstra group's publication was chosen due to the impact their technology is expected to have. "This technology will hasten the promise of regenerative medicine and the therapeutic possibilities of umbilical cord blood and hematopoietic stem cells in particular. It is very likely that Fed-Batch technology will improve the outcome of blood system transplants for many patients. We are proud to award the 2013 lecture … Continue reading →

CARLSBAD, CA--(Marketwired - Sep 26, 2013) - International Stem Cell Corporation (OTCQB: ISCO) (www.internationalstemcell.com), a California-based biotechnology company developing novel stem cell based therapies and biomedical products, announced today that it will participate in the 12th Annual BIO Investor Forum hosted by the Biotechnology Industry Organization (BIO). The conference is being held October 8-9th, 2013, at the Palace Hotel in San Francisco, CA. Dr. Simon Craw, Executive Vice President, will provide an overview of the Company's business during the live presentation and will be available to participate in one-on-one meetings with investors who are registered to attend the conference. Date: Wednesday, October 9, 2013 Time: 2:00 p.m. Pacific Time Location: Palace Hotel, Presidio Room Follow the official conference feed on Twitter, and join the conversation by using #BIF13. About International Stem Cell Corporation International Stem Cell Corporation is focused on the therapeutic applications of human parthenogenetic stem cells (hpSCs) and the development and commercialization of cell-based research and cosmetic products. ISCO's core technology, parthenogenesis, results in the creation of pluripotent human stem cells from unfertilized oocytes (eggs). hpSCs avoid ethical issues associated with the use or destruction of viable human embryos. ISCO scientists have created the first parthenogenic, homozygous stem … Continue reading →

Public release date: 26-Sep-2013 [ | E-mail | Share ] Contact: Graham Shaw graham.shaw@icr.ac.uk 44-020-715-35380 Institute of Cancer Research Scientists have used a brand new technique for examining individual stem cells to uncover dramatic differences in the gene expression levels which genes are turned 'up' or 'down' between apparently identical 'sister' pairs. The research, published today (Thursday) in Stem Cell Reports, was conducted and funded by The Institute of Cancer Research, London. It provides the latest evidence that despite having identical DNA, sister stem cells can display considerable differences in their molecular characteristics. The study showed that DNA methylation, a process that controls which genes are expressed in cells, plays an important role in generating non-genetic (or 'epigenetic') differences between sister cells. DNA methylation could therefore be one of the reasons for the major molecular variation between different cancer cells in the same tumour and drugs to reduce methylation might help control variation and make cancers easier to treat. In the new research, scientists at The Institute of Cancer Research (ICR) developed a novel micro-dissection technique to separate pairs of sister embryonic stem cells for single cell RNA analysis [1]. Using their new high-tech method, researchers separated and isolated mouse … Continue reading →